- Home
- RNAC
as 12-18-2024 9:58am EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 422.4M | IPO Year: | 2016 |
| Target Price: | $41.60 | AVG Volume (30 days): | 113.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.67 - $41.87 | Next Earning Date: | 11-07-2024 |
| Revenue: | $47,938,000 | Revenue Growth: | -62.40% |
| Revenue Growth (this year): | 56.06% | Revenue Growth (next year): | -84.20% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kurtoglu Metin | RNAC | Chief Technology Officer | Dec 9 '24 | Sell | $25.15 | 13,664 | $345,133.86 | 51,033 | |
| Kurtoglu Metin | RNAC | Chief Technology Officer | Nov 19 '24 | Sell | $17.88 | 38,689 | $649,029.56 | 51,033 | |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Nov 14 '24 | Buy | $17.33 | 431,940 | $7,373,527.21 | 8,097,923 | |
| Kurtoglu Metin | RNAC | Chief Technology Officer | Nov 14 '24 | Sell | $17.47 | 82,368 | $1,438,037.68 | 51,033 | |
| Jewell Christopher M | RNAC | Chief Scientific Officer | Nov 14 '24 | Sell | $16.81 | 52,115 | $875,042.30 | 25,940 | |
| Miljkovic Milos | RNAC | Chief Medical Officer | Nov 14 '24 | Sell | $16.64 | 55,000 | $907,532.50 | 18,273 | |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Oct 2 '24 | Buy | $20.91 | 205,721 | $4,293,544.83 | 8,097,923 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
TipRanks
14 days ago
Cartesian Therapeutics Reports Promising Phase 2b Trial Results
GlobeNewswire
15 days ago
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
GlobeNewswire
a month ago
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Simply Wall St.
a month ago
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics
GuruFocus.com
a month ago
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
GlobeNewswire
a month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
a month ago
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.